Synthesis 2015; 47(06): 817-826
DOI: 10.1055/s-0034-1379887
paper
© Georg Thieme Verlag Stuttgart · New York

Tricyclic Fused Pyrazoles with a ‘Click’ 1,2,3-Triazole Substituent in Position 3 Are Nanomolar CB1 Receptor Ligands

Authors

  • Chiara Zanato

    a   Kosterlitz Centre for Therapeutics, Institute of Medical Sciences, University of Aberdeen, Foresterhill, AB25 2ZD, Scotland, UK   Email: m.zanda@abdn.ac.uk
  • Maria Grazia Cascio

    a   Kosterlitz Centre for Therapeutics, Institute of Medical Sciences, University of Aberdeen, Foresterhill, AB25 2ZD, Scotland, UK   Email: m.zanda@abdn.ac.uk
  • Paolo Lazzari*

    b   PharmaNess Scarl, Parco Scientifico della Sardegna, Edificio 5, Loc. Piscinamanna, 09010 Pula (CA), Italy
    c   KemoTech s.r.l., Parco Scientifico della Sardegna, Edificio 3, Loc. Piscinamanna, 09010 Pula (CA), Italy
  • Roger Pertwee

    a   Kosterlitz Centre for Therapeutics, Institute of Medical Sciences, University of Aberdeen, Foresterhill, AB25 2ZD, Scotland, UK   Email: m.zanda@abdn.ac.uk
  • Andrea Testa

    a   Kosterlitz Centre for Therapeutics, Institute of Medical Sciences, University of Aberdeen, Foresterhill, AB25 2ZD, Scotland, UK   Email: m.zanda@abdn.ac.uk
  • Matteo Zanda*

    a   Kosterlitz Centre for Therapeutics, Institute of Medical Sciences, University of Aberdeen, Foresterhill, AB25 2ZD, Scotland, UK   Email: m.zanda@abdn.ac.uk
    d   C.N.R.-I.C.R.M., via Mancinelli 7, 20131 Milano, Italy
Further Information

Publication History

Received: 19 November 2014

Accepted: 12 December 2014

Publication Date:
16 January 2015 (online)


Graphical Abstract

Preview

Abstract

Structural modification of the potent conformationally constrained tricyclic pyrazole CB1 ligand NESS0327 was achieved by replacing: (1) the chlorine substituent on the tricycle with a 3-fluoropropyl chain, and (2) the pyrazole 3-{[(piperidino)amino]carbonyl} substituent with a 4-substituted 1,2,3-triazole group obtained by click chemistry from an alkynyl precursor. Among the resulting compounds, two are particularly promising candidates for [18F]radiolabelling and PET imaging studies of the CB1 receptor, as they displayed K i CB1 = 62.5 nM and 42.5 nM, respectively, in the same range as that displayed by rimonabant.

Supporting Information